Dual antiplatelet therapy (DAPT) duration often depends on the patient—and it may depend on the stent as well.
XIENCE™ Stent is the only DES with results showing 1-month DAPT data and 3-month DAPT data for both aspirin and P2Y12 inhibitor monotherapy—including data on patients at high bleeding risk (HBR).4
Among all 3 categories outlined above—aspirin monotherapy, P2Y12 inhibitor monotherapy and HBR patients—XIENCE™ Stent data revealed very low rates of stent thrombosis (ST) at 12 months.5
≤ 0.3% Definite ST At 1 Year5
Among HBR patients, XIENCE™ Stent with 1-month or 3-month DAPT reduced severe bleeding with no increase in ischemic events, including myocardial infarction (MI) and all death.6
In the same HBR population, XIENCE™ Stent with 1-month or 3-month DAPT reduced severe bleeding with no increase in ischemic events.6,*
*Propensity score stratified analysis for BARC 3-5 bleeding was not pre-specified. BARC 2-5 was a powered secondary endpoint. In both studies, for BARC 2-5, XIENCE™ Stent showed numerically lower bleeding rate for 1-month or 3-month DAPT versus 6-month DAPT or 12-month DAPT, respectively.
XIENCE™ Stent is recognized for its low ST rate, and it is significantly more anti-thrombotic than other DES.7 This is evident even with short DAPT data. XIENCE™ Stent with 1-month DAPT showed no increase in ST vs 6-month DAPT—with an ST rate of 0.3%. Similarly, the 3-month DAPT showed an ST rate of 0.2%.6
The XIENCE™ Stent is also recognized as being significantly more anti-thrombotic than other DES on the market. As shown in the study findings, XIENCE™ Stent reveals significantly less (p < 0.01) platelet adhesion—shown in red in the confocal microscopy images—than other DES, and platelet adhesion is an important factor in stent thrombosis.*8 These findings suggest that this stent choice “may be ideally suited for very short-term DAPT.”8
*Ex Vivo Swine Shunt Model.
STOPDAPT9 and STOPDAPT 210 were prospective trials of the XIENCE™ Stent that studied DAPT cessation at 3 months and 1 month, respectively
The STOPDAPT 2 trial revealed that 1-month DAPT demonstrated superior safety over 12-month DAPT for the primary endpoint of net adverse cardiovascular events (NACE). NACE included cardiovascular death, myocardial infarction (MI), definite ST, stroke, or thrombolysis in MI (TIMI) major/minor bleeding. All of the 3,009 patients in this randomized, controlled trial were treated with XIENCE™ Stent.10
STOPDAPT9 was the first prospective trial to study DAPT cessation at 3 months after implantation. Among other 1-year outcomes, the XIENCE™ Stent rate of stent thrombosis was 0.0%.
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?